Malignant Glioma Treatment Market By Treatment Type (Surgical Treatment {Craniotomy, Stereotactic Biopsy, Endoscopic Surgery}, Radiation Therapy {External Beam Radiation Therapy, Stereotactic Radiosurgery, Brachytherapy}, Chemotherapy {Alkylating Agents, Nitrosoureas, Antimetabolites}, Targeted Therapy {EGFR Inhibitors, VEGF Inhibitors, mTOR Inhibitors}, Medication {Alkylating Agents, Angiogenesis Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Corticosteroids}, Immunotherapy, Gene Therapy), By Tumor Type (Astrocytomas, Oligodendrogliomas, Ependymomas, Glioblastoma Multiforme (GBM)), By Route of Administration (Oral, Intravenous (IV), Intrathecal), By End User (Hospitals, Specialty Clinics, Cancer Treatment Centers, Research & Academic Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Malignant Glioma Treatment Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing cases of glioblastoma and other aggressive brain tumors drive demand for advanced treatment options.

3.2.2. As the elderly population grows, so does the risk of gliomas, increasing demand for effective treatments

3.2.3. Advancements in genomics and biomarker-based treatments support customized therapies for better patient outcomes

3.3. Key industry pitfalls & challenges

3.3.1. Advanced glioma treatments, including surgery, radiation, and targeted therapies, are expensive

3.3.2. Chemotherapy, radiation, and targeted drugs can cause significant side effects, affecting patient quality of life

3.3.3. Many gliomas are diagnosed at an advanced stage, reducing the effectiveness of available treatments

3.4. Market Opportunities

3.4.1. Increased research and clinical trials in immunotherapy, offer promising new treatment avenues

3.4.2. Rising adoption of endoscopic and robotic-assisted surgeries enhances patient recovery and treatment efficiency

3.4.3. Improved radiation techniques enable more precise tumor targeting with minimal damage to healthy tissues

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Malignant Glioma Treatment Market, Treatment Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Treatment Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Surgical Treatment

4.2.1. Craniotomy

4.2.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Stereotactic Biopsy

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Endoscopic Surgery

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Radiation Therapy

4.3.1. External beam Radiation Therapy

4.3.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Stereotactic Radiosurgery

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Brachytherapy

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Chemotherapy

4.4.1. Alkylating Agent

4.4.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.2. Nitrosoureas

4.4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.3. Antimetabolites

4.4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Targeted Therapy

4.5.1. EGFR Inhibitors

4.5.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5.2. VEGF Inhibitors

4.5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5.3. mTOR Inhibitors

4.5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Medication

4.6.1. Alkylating Agents

4.6.1.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6.2. Angiogenesis Inhibitors

4.6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6.3. Tyrosine kinase Inhibitors (TKIs)

4.6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6.4. Corticosteroids

4.6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Immunotherapy

4.8. Gene Therapy

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Malignant Glioma Treatment Market, Tumor Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Tumor Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Astrocytomas

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Oligodendrogliomas

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Ependymomas

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Glioblastoma Multiforme (GBM)

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Malignant Glioma Treatment Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oral

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Intravenous (IV)

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Intrathecal

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Malignant Glioma Treatment Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Specialty Clinics

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Cancer Treatments Centers

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Research & Academic Institutes

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Malignant Glioma Treatment Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Treatment Type, 2025-2035

8.2.3. North America Market Revenue, By Tumor Type, 2025-2035

8.2.4. North America Market Revenue, By Route of Administration, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Treatment Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Tumor Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Route of Administration, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Treatment Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Tumor Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Route of Administration, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Treatment Type, 2025-2035

8.3.3. Europe Market Revenue, By Tumor Type, 2025-2035

8.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Treatment Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Tumor Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Route of Administration, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Treatment Type, 2025-2035

8.3.7.2. France Market Revenue, By Tumor Type, 2025-2035

8.3.7.3. France Market Revenue, By Route of Administration, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Treatment Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Tumor Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Route of Administration, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Treatment Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Tumor Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Route of Administration, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Treatment Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Tumor Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Route of Administration, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Treatment Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Tumor Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Tumor Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Treatment Type, 2025-2035

8.4.6.2. China Market Revenue, By Tumor Type, 2025-2035

8.4.6.3. China Market Revenue, By Route of Administration, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Treatment Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Tumor Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Route of Administration, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Treatment Type, 2025-2035

8.4.8.2. India Market Revenue, By Tumor Type, 2025-2035

8.4.8.3. India Market Revenue, By Route of Administration, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Treatment Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Tumor Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Route of Administration, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Treatment Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Tumor Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Route of Administration, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Treatment Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Tumor Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Route of Administration, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Tumor Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.3. Latin America Market Revenue, By Tumor Type, 2025-2035

8.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Treatment Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Tumor Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Route of Administration, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Treatment Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Tumor Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Route of Administration, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Treatment Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Tumor Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Route of Administration, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Tumor Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Treatment Type, 2025-2035

8.6.3. MEA Market Revenue, By Tumor Type, 2025-2035

8.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Treatment Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Tumor Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Treatment Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Tumor Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Route of Administration, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Treatment Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Tumor Type, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. Merck & Co., Inc.

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Bristol-Myers Squibb Company

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. F. Hoffmann-La Roche Ltd

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Bio-Rad Laboratories

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Azurity Pharmaceuticals, Inc.

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Amgen, Inc.

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Pfizer Inc.

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Teva Pharmaceutical Industries Ltd.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Sun Pharmaceutical Industries Ltd.

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Boston Biomedical, Inc.

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Arbor Pharmaceuticals, LLC

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Amneal Pharmaceuticals

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Karyopharm Therapeutics, Inc.

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Bayer AG

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. AstraZeneca PLC

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis